Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2025

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

Presenter: Yuko Kiyohara

October 27, 2025

Presentation TCT 2025

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

Presenter: Bhagya Harindi Loku Waduge

October 27, 2025

Presentation TCT 2025

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Presenter: Kamil Bujak

October 27, 2025

Presentation TCT 2025

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

Presenter: Ulf Teichgräber

October 26, 2025

Presentation TCT 2025

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

Presenter: Seung-Whan Lee

October 26, 2025

Presentation TCT 2025

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

Presenter: Christina Lalani

October 26, 2025

Presentation TCT 2025

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

Presenter: Neal S. Kleiman

October 26, 2025

Presentation TCT 2025

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Aditya Mantha

October 26, 2025

Presentation TCT 2025

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Presenter: Prakriti Gaba

October 26, 2025

Presentation TCT 2025

Real-World Registry of Paclitaxel Drug-Coated Balloon for Native Coronary Artery Disease Treatment

Presenter: Masato Nakamura

October 25, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

Advertisement

TCT 467: Comparative Long-Term Outcomes Of Sirolimus vs Paclitaxel-Coated Balloons In STEMI: A Retrospective Analysis

TCT 468: Comparison of Limus and Paclitaxel Drug-Coated Balloons, 2nd-generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials

TCT 469: Comparative Outcomes of Sirolimus versus Paclitaxel-Coated Balloon Angioplasty in De Novo Coronary Lesions: Real-World Data

TCT 515: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

TCT 510: Real-World Usage of a Prevail Paclitaxel-Coated Balloon Compared With Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

TCT 511: Paclitaxel-Coated Balloons versus Newer-Generation Drug-Eluting Stents for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Controlled Trials

Two-year Outcome of Sirolimus-coated Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: Evidence from the Randomized SIRONA Trial

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

TCT 178: Use of the AGENT Paclitaxel-Coated Balloon in the United States Shortly After FDA Approval: Early Results from the AGENT Post-Approval Study

TCT 180: Paclitaxel-Coated Balloon versus Uncoated Balloon for Coronary In-Stent Restenosis in Patients with Acute Coronary Syndromes: A Subanalysis of the AGENT IDE Trial

TCT 182: Impact of Lesion Preparation Strategy on the Efficacy of Paclitaxel Coated Balloon for Coronary In-stent Restenosis: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 181: Efficacy and Safety of Coronary Angioplasty Using a Paclitaxel-Coated vs Uncoated Balloon in Patients with In-Stent Restenosis Stratified by Restenosis Risk: A Subanalysis of the AGENT IDE

Real-World Registry of Paclitaxel Drug-Coated Balloon for Native Coronary Artery Disease Treatment

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content